NCT05069051 - Belimumab in Patients with Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

January 19, 2022

Primary Completion Date

July 15, 2026

Study Completion Date

July 14, 2027

Conditions

Chronic Lymphoid Leukemia in Relapse

Interventions

DRUG

Belimumab 200 MG/ML [Benlysta]

Patients obtain belimumab treatment in combination with rituximab and venetoclax

DRUG

standard of care

Patients obtain the standard of care: combination rituximab and venetoclax

Trial Locations (1)

University Hospital Tuebingen, CCU Translational Immunology, Tübingen